Vitamin D research-
1 post
• Page 1 of 1
Vitamin D research-
Vitamin D Levels.
Peppone LJ, Rickles AS, Janelsins MC, Insalaco MR, Skinner KA.
Department of Radiation Oncology, University of Rochester Medical Center,
Rochester, New York, NY, USA, luke_peppone@urmc.rochester.edu.
BACKGROUND: Studies show that women with low vitamin D levels have an increased risk of breast cancer (BC) incidence and mortality, but there is a lack of research examining vitamin D levels and prognostic variables in BC patients. The aim of this study is to examine 25-OH vitamin D levels between BC cases and controls and by prognostic indicators among BC cases. METHODS: 25-OH vitamin D levels were collected from 194 women who underwent BC surgery and 194 cancer-free(CF) controls at the University of Rochester between January 2009 and October2010.
Mean 25-OH vitamin D levels and odds ratios (OR) were calculated by
case/control status for the overall cohort and by prognostic indicators
(invasiveness, ER status, triple-negative status, Oncotype DX score, molecular phenotype) for BC cases. RESULTS: BC cases had significantly lower 25-OH vitamin D levels than CF controls (BC: 32.7 ng/mL vs. CF: 37.4 ng/mL; P = .02). In case-series analyses, women with suboptimal 25-OH vitamin D concentrations(<32 ng/mL) had significantly higher odds of having ER- (OR = 2.59, 95% confidence interval [95% CI] = 1.08-6.23) and triple-negative cancer (OR = 3.15, 95% CI = 1.05-9.49) than those with optimal 25-OH D concentrations. Women with basal-like phenotype had lower 25-OH vitamin D levels than women luminal A phenotype (basal-like: 24.2 ng/mL vs. luminal A: 32.8 ng/mL; P = 0.04).
CONCLUSIONS: BC patients with a more aggressive molecular phenotype (basal-like) and worse prognostic indicators (ER- and triple-negative) had lower mean 25-OH vitamin D levels. Further research is needed to elucidate the biological relationship between vitamin D and BC progression.
PMID: 22446898 [PubMed - as supplied by publisher]
2. J Womens Health (Larchmt). 2012 Apr;21(4):456-62. Epub 2012 Mar 2.
Vitamin d deficiency in postmenopausal breast cancer survivors.
Friedman CF, Demichele A, Su HI, Feng R, Kapoor S, Desai K, Mao JJ.
1 Abramson Cancer Center, University of Pennsylvania Health System ,
Philadelphia, Pennsylvania.
Abstract Purpose: Breast cancer survivors (BCS) taking aromatase inhibitors (AIs)are at an increased risk for decreased bone density and fractures. Given the role vitamin D plays in bone metabolism, we examined the prevalence of and risk factors for vitamin D deficiency in a study of postmenopausal BCS on AIs.
Methods: We collected data on 391 postmenopausal women with stage I-III breast cancer on AI therapy. Vitamin D levels were measured by radioimmunoassay from patients' sera; deficiency was defined as a level < 30 ng/mL. Multivariate models were created to assess risk factors for deficiency.
Results: The median vitamin D level was 35 ng/mL (range 6.78-93.15), and 35% of women were vitamin D deficient.When adjusting for age and vitamin D supplementation, minority participants were more likely to be vitamin D deficient than white women, (adjusted odds ratio[AOR] 2.18, 95% confidence interval [CI]1.22-3.89, p=0.009). Both overweight (AOR3.05, 95% CI 1.72-5.41, p<0.001) and obese participants (AOR 3.21, 95% CI
1.79-5.78, p<0.001) had higher deficiency rates than did normal weight
participants.
Conclusions: Hypovitaminosis D is common in BCS, and those who are
nonwhite or overweight are at a higher risk of deficiency despite taking vitamin
D supplements.
-
Judith - Site Admin
- Posts: 280
- Joined: Wed Sep 25, 2013 5:08 pm
1 post
• Page 1 of 1
Who is online
Users browsing this forum: No registered users and 49 guests